Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8381805eba6d034fc77bd230dd02e6e2 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395 |
filingDate |
2007-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5505f8d1d3a9635af98a175498c958a6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_778601f3e309514a13b3dbf8a523ce73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59fbe334d5dc6c296514fd19372c9ecf |
publicationDate |
2012-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-2433635-A1 |
titleOfInvention |
PAK Modulators |
abstract |
The present invention provides methods for treating fragile X syndrome and/or other neurodevelopmental disorders by administering p21-activated kinase (PAK) modulators to a patient suffering from, susceptible to, and/or exhibiting one or more symptoms of FXS and/or other neurodevelopmental disorders. The present invention provides PAK modulators and pharmaceutical compositions comprising PAK modulators. The present invention further provides methods for identifying and/or characterizing PAK modulators. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014076235-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2732815-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10201507-B2 |
priorityDate |
2006-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |